Drug intelligence / Profile preview

ARN-75092

Development stage: Preclinical
Lead developer: Arisan Therapeutics
Modality: Small Molecules

Overview

ARN-75092 is a small molecule antiviral candidate developed by Arisan Therapeutics for the treatment of Ebolavirus infections. It functions as a fusion and cell entry inhibitor by targeting viral glycoproteins (GP), which are essential for the virus to attach to and enter host cells. By blocking this initial stage of the viral life cycle, ARN-75092 aims to prevent the systemic spread of the virus within the host. It is part of Arisan's pipeline focusing on high-consequence viral pathogens.

Beyond the preview

Go deeper on ARN-75092.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARN-75092.

Explore the full profile